• LMO2–LDB1 Drives AML Progression: Study Insights

  2026-09-01

  This study identifies an LMO2/LDB1 protein complex as a functional regulator of acute myeloid leukemia cell proliferation and survival, extending LMO2 biology beyond its association with hematopoiesis and prognosis. By combining genetic perturbation, proteomics, interaction assays, transcriptomics, ChIP-seq, rescue experiments, and in vivo validation, the authors propose LDB1-dependent regulation of apoptosis-related programs as a mechanistic route to AML maintenance.

• ABT-199 and the Next Era of Apoptosis Research

  2026-09-01

  ABT-199, also known as Venetoclax, is more than a potent BCL-2 inhibitor: it is a precise probe for testing whether mitochondrial dependence explains cancer-cell death. By combining selective pharmacology with time-resolved death-rate analysis, translational researchers can build stronger biomarker and resistance hypotheses.

• AZ505: Selective SMYD2 Inhibitor for Research

  2026-08-31

  AZ505 is a substrate-competitive SMYD2 inhibitor that blocks peptide-substrate methylation without directly competing with SAM. Its reported biochemical potency, enzyme selectivity, and use in cisplatin-induced renal fibrosis models support epigenetic regulation research and cancer biology research.

• Caspase-3 Fluorometric Assay Kit for Cell-Fate Mapping

  2026-08-31

  The Caspase-3 Fluorometric Assay Kit converts DEVD-dependent protease activity into a quantitative fluorescence readout. This guide explains how to use that signal to distinguish executioner-caspase activation from ferroptosis-associated PARP1 changes, with practical controls for stronger apoptosis research.

• KPT330 and Precision CRISPR-Cas9 Editing

  2026-08-30

  The reference study identifies KPT330 and related selective inhibitors of nuclear export as indirect, irreversible modulators of Cas9 activity. By regulating Cas9 mRNA nuclear export rather than binding the Cas9 enzyme directly, these compounds improved the specificity of genome-, base-, and prime-editing systems in human cells.

• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer

  2026-08-29

  The reference study developed chemically modified CDKN1A/p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its preclinical data connect bladder-localized p21 restoration with cell-cycle inhibition, DNA damage, apoptosis, and reduced orthotopic tumor growth, while also identifying important translational limits.

• Protein A/G Magnetic Co-IP/IP Kit for BATF2–ATF3

  2026-08-28

  Discover how the Protein A/G Magnetic Co-IP/IP Kit can test BATF2–ATF3 interaction hypotheses in intervertebral disc degeneration. This guide focuses on assay architecture, controls, complex preservation, and the limits of interpreting co-immunoprecipitation as mechanistic evidence.

• O-GlcNAcylation Rewires Wnt-Driven Bone Formation

  2026-08-28

  The reference study identifies O-GlcNAcylation as a metabolic and post-translational mechanism linking Wnt stimulation to osteoblast formation. Its experiments show that Wnt3a stabilizes PDK1 through modification at Ser174, thereby increasing aerobic glycolysis and supporting bone formation and fracture healing.

• GDC-0941: Reading PI3K Signals in Tumor Models

  2026-08-27

  GDC-0941 is a PI3K inhibitor whose value extends beyond simple pathway suppression. This article presents a phenotype-aware strategy for connecting PI3K/Akt measurements with proliferation, apoptosis, therapy resistance, and EMT-related assay decisions.

• Coil-Bottlebrush Networks in Ionic Liquids

  2026-08-27

  The 2024 Macromolecules study examines how coil-bottlebrush diblock copolymers form lyotropic nanostructures in alkylimidazolium ionic liquids with systematically varied alkyl-chain lengths. Its central finding is that phase behavior depends surprisingly weakly on ionic-liquid identity, suggesting that polymer architecture and packing can buffer substantial changes in solvent selectivity.

• 6-FAM SE Workflows for Durable Biomolecule Labeling

  2026-08-26

  6-FAM SE enables stable, amine-directed fluorescent labeling of oligonucleotides, proteins, and peptides for sensitive molecular assays. This practical guide connects NHS-ester chemistry with reproducible workflows, troubleshooting, and assay-design lessons inspired by a glutathione-responsive melanoma nanomedicine study.

• Anlotinib Hydrochloride: Mechanism to Assay

  2026-08-26

  Anlotinib hydrochloride offers a mechanism-informed way to study angiogenesis rather than treating tube formation as an isolated endpoint. This guide connects VEGFR2, PDGFRβ, FGFR1, and ERK signaling pathway inhibition with assay design, interpretation, pharmacology, and translational limits.

• SEMA3E Drives Beige Adipocyte Thermogenesis in Mice

  2026-08-25

  This 2026 mouse study identifies SEMA3E as a regulator of beige adipocyte differentiation and cold-induced thermogenesis, linking its activity to mitochondrial oxidative phosphorylation and β-catenin signaling. Loss- and gain-of-function experiments, adipose transplantation, AAV knockdown, RNA sequencing, and respiration assays provide a mechanistic framework for studying adipose tissue plasticity in metabolic research.

• Oleic Acid in Hepatic Lipid Stress Models

  2026-08-25

  Explore how Oleic Acid (C18:1(9Z)) can be used to build and interpret hepatocyte lipid-stress assays. This article connects fatty-acid model design with the AMPK, SREBP2, and LXRα findings of a recent hepatic ischemia-reperfusion study.

• Tariquidar Workflows for Viscosity-Driven Resistance

  2026-08-24

  Tariquidar (XR9576) helps researchers distinguish P-glycoprotein-mediated efflux from mechanical stress in tumor models. This practical guide combines viscosity manipulation, transporter assays, mechanistic readouts, and troubleshooting for stronger drug resistance research.

7926 records 1/529 page Next 12345 下5页 Last page